Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

Abstract: The present application provides solid forms and salts of a compound of Formula (I): pharmaceutical compositions thereof, methods of treating a disease or disorder associated with CDK2 using the same, and processes of preparing the compound of Formula (I) and the solid forms and salts.

Abstract: This application relates to processes and intermediates for the preparation of the PD-1/PD-L1 inhibitor (R)-1-((7-cyano-2-(3?-((2-(difluoromethyl)-7-((3-hydroxypyrrolidin-1-yl)methyl)pyrido[3,2-d]pyrimidin-4-yl)amino)-2,2?-dimethyl-[1,1?-biphenyl]-3-yl)benzo[d]oxazol-5-yl)methyl)piperidine-4-carboxylic acid, and salts and crystalline forms thereof, where the PD-1/PD-L1 inhibitor and solid forms and salt forms thereof are useful in the treatment of various diseases including infectious diseases and cancer.

Abstract: Provided herein are processes and intermediates useful for the preparation of certain compounds, including a compound of formula 21 or formula 22 or a pharmaceutically acceptable salt of either.

Abstract: Aircraft radome apparatuses and methods are described. In some examples, a radome is to be mounted on an aircraft. In some examples, the radome includes an outer mold line having a closure angle. In some examples, the closure angle is configured to reduce a footprint of the radome. In some examples, the closure angle is also configured to reduce a likelihood of separated airflow from occurring proximate a trailing portion of the radome during a flight of the aircraft. In some examples, the radome is to be mounted on the aircraft at a location that reduces a rate of change of a transverse cross-sectional area of the aircraft.

Abstract: Aircraft radome apparatuses and methods are described. In some examples, a radome is to be mounted on an aircraft. In some examples, the radome includes an outer mold line having a closure angle. In some examples, the closure angle is configured to reduce a footprint of the radome. In some examples, the closure angle is also configured to reduce a likelihood of separated airflow from occurring proximate a trailing portion of the radome during a flight of the aircraft. In some examples, the radome is to be mounted on the aircraft at a location that reduces a rate of change of a transverse cross-sectional area of the aircraft.

Abstract: This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Abstract: This invention is directed to asymmetric synthesis of funapide, which is useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.

Abstract: The present invention provides an efficient, safe and cost effective way to prepare 5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is a key intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II):

Abstract: The present invention provides an efficient, safe and cost effective way to prepare 5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is a key intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II):

Abstract: The present invention provides an efficient, safe and cost effective way to prepare 5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is a key intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II):

Abstract: The present invention provides an efficient, safe and cost effective way to prepare 5-(4-methyl-1H-imidazol-1-yl)-3-(trifluoromethyl)-benzenamine which is a key intermediate for the preparation of substituted pyrimidinylaminobenzamides of formula (II):